Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine

SynCardia provides the only FDA approved total artificial heart and a foundation for next generation fully implantable solutions.

What problem does Picard Medical solve?

Picard Medical / SynCardia is addressing one of the largest and fastest growing unmet needs in cardiovascular medicine. The Company’s SynCardia Total Artificial Heart replaces the circulatory functions of a failing human heart, sustaining patients who would otherwise not survive while they wait for a donor organ.

Advanced heart failure continues to rise globally, while the supply of donor hearts remains limited. This structural imbalance creates a significant and expanding market opportunity, with thousands of patients each year lacking viable treatment options and placing growing economic pressure on healthcare systems.

Unlike ventricular assist devices that support a weakened native heart, the SynCardia Total Artificial Heart fully replaces the heart’s pumping function and provides complete circulatory support. SynCardia’s technology is the only FDA approved total artificial heart available today, supported by established clinical use, reimbursement, and a growing global implant base.

As transplant waiting lists grow and organ supply remains limited, solutions that sustain patients long enough to receive a donor heart are becoming increasingly important in cardiac care. The Company is focused on scaling this platform while advancing next generation fully implantable solutions designed to expand life supporting opportunities for heart failure patients the market and improve patient outcomes.

‍

For more information on Picard Medical (NYSE: PMI) please click on the request investor info button.

‍